Barrington Research Begins Coverage on Bioventus (NYSE:BVS)

Analysts at Barrington Research assumed coverage on shares of Bioventus (NYSE:BVS) in a research report issued on Monday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $13.00 price target on the stock. Barrington Research’s price objective would suggest a potential upside of 61.09% from the company’s previous close.

Bioventus Stock Performance

NYSE:BVS opened at $8.07 on Monday. Bioventus has a twelve month low of $5.81 and a twelve month high of $11.25. The firm has a market capitalization of $667.90 million, a price-to-earnings ratio of -13.23 and a beta of 0.80. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The firm’s fifty day simple moving average is $7.73 and its 200 day simple moving average is $7.29.

Insider Activity

In other news, Director Guy P. Nohra sold 10,000 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $7.57, for a total transaction of $75,700.00. Following the transaction, the director directly owned 116,610 shares of the company’s stock, valued at approximately $882,737.70. The trade was a 7.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 33.00% of the stock is owned by corporate insiders.

Institutional Trading of Bioventus

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Anderson Financial Strategies LLC acquired a new stake in shares of Bioventus during the third quarter worth approximately $901,000. Campbell & CO Investment Adviser LLC bought a new position in shares of Bioventus in the 2nd quarter worth about $449,000. Allspring Global Investments Holdings LLC lifted its position in shares of Bioventus by 79.4% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 66,067 shares of the company’s stock worth $437,000 after buying an additional 29,238 shares during the last quarter. Segall Bryant & Hamill LLC boosted its holdings in shares of Bioventus by 468.9% in the 2nd quarter. Segall Bryant & Hamill LLC now owns 281,849 shares of the company’s stock valued at $1,866,000 after buying an additional 232,302 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Bioventus by 13.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,054,903 shares of the company’s stock valued at $6,984,000 after buying an additional 122,137 shares during the last quarter. 62.94% of the stock is owned by hedge funds and other institutional investors.

About Bioventus

Bioventus, Inc (NYSE: BVS) is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus’s product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement.